“…Neurons and other brain cells take up Aβ peptides as a necessary step in BBB clearance, and intracellular digestion of these peptides via the ubiquitin–proteasome system (UPS) and the lysosomes has been demonstrated, as reviewed. , However, digestion of extracellular Aβ peptides by individual extracellular or external membrane-bound proteases has gained more attention as a possible culprit in AD and a facile target for intervention. In some cases, a relationship between the enzyme expression level and its activity or inhibition was correlated with the progression of disease in humans or experimental animals. ,− Proteases listed in the context of Aβ degradation include insulin-degrading enzyme (IDE), neprilysin (NEP), matrix metalloproteinases (MMPs), especially MMP2, MMP7, and MMP9, angiotensin-converting enzyme (ACE), endothelin-converting enzymes (ECE1 and ECE2), and plasmin. Indeed, the catabolic activity of any individual protease is not likely to suffice to account for AD pathology, but rather the actions of anabolic and catabolic enzymes sum up to a dynamic Aβ equilibrium level, which may evolve with age as malfunctions of various metabolic pathways, including proteolysis and clearance, accrue …”